Archive

Awareness of lung cancer screening remains low

Written by Charlie King | 10 Nov 2024

There is a lung cancer screening test that is saving lives – and yet most people who could be getting the test have never heard of it or… read more.

Researchers quantify the benefit of quitting smoking soon after cancer diagnosis

Written by Charlie King | 7 Nov 2024

Quitting smoking within six months after a cancer diagnosis adds an average of two years to a patient’s life. With this information in hand, all cancer centers have… read more.

Plus Therapeutics to present groundbreaking CNS cancer treatment data at 2024 neuro-oncology conference in Texas

Written by Charlie King | 29 Oct 2024

Plus Therapeutics a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, will have multiple opportunities to present data at the… read more.

Emotional and financial concerns of breast cancer patients are often unmet

Written by Charlie King | 22 Oct 2024

Although breast cancer is the most common non-skin cancer diagnosed in women, finding support during treatment and through survivorship can be incredibly challenging. An analysis of posts from… read more.

Application submitted for third indication of darolutamide in the EU – Bayer

Written by Charlie King | 19 Oct 2024

Bayer announced the submission of an application to the European Medicines Agency (EMA) for the oral androgen receptor inhibitor (ARi) darolutamide. Bayer is seeking approval for the use… read more.

Immunotherapy with nivolumab increases survival in advanced Hodgkin lymphoma

Written by Bruce Sylvester | 17 Oct 2024

An investigative immunotherapy regimen for advanced Hodgkin lymphoma has increased the survival rate from 80 percent to 92 percent, researchers reported on Oct. 17, 2024 in the NEJM/New… read more.

Johnson & Johnson extended filing at EMA for Darzalex (daratumumab subcutaneous) + R-VDd for newly diagnosed multiple myeloma

Written by Charlie King | 15 Oct 2024

Janssen-Cilag International NV, a Johnson & Johnson company, announced the submission of a Type II variation application to the European Medicines Agency (EMA) seeking approval for an indication… read more.

Significant worldwide disparities in availability and timeliness of new cancer drugs

Written by Charlie King | 14 Oct 2024

Despite considerable progress in the discovery and development of new cancer drugs, there are significant disparities in both the availability and timeliness of these medicines worldwide, with poorer… read more.

Positive CHMP opinion for mirvetuximab soravtansine for the treatment of certain ovarian cancer – AbbVie

Written by Charlie King | 6 Oct 2024

AbbVie announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the marketing authorization of mirvetuximab soravtansine… read more.

Most accurate ultrasound test could detect 96% of women with ovarian cancer

Written by Charlie King | 5 Oct 2024

An ultrasound test that detected 96% of ovarian cancers in postmenopausal women should replace current standard of care test in the UK according to a new study. In… read more.

Ontario Institute for Cancer Research funding aims to speed the development of new drugs for some of the most common cancers

Written by Charlie King | 4 Oct 2024

The Ontario Institute for Cancer Research (OICR) continues to support Ontario drug discovery research by funding high-quality investigations of new therapies for some of the most prevalent pediatric… read more.

Positive CHMP opinion for mirvetuximab soravtansine (Elahere) for the treatment of certain adult ovarian cancer – AbbVie

Written by Charlie King | 25 Sep 2024

1 2 3 … 37 Next »

Archive

Subscribe for our mailing list

Follow Us